Green Cross Cell, ToolGen to collaborate on cancer therapy

[THE INVESTOR] Cell therapy developer Green Cross Cell and biotechnology firm ToolGen on Aug. 22 signed a memorandum of understanding on collaborating in developing immune therapy for cancer.

The two companies plan to apply ToolGen’s DNA scissor technology to Green Cross Cell’s anti-cancer immune therapy.

The companies hope to amplify T-cells’ ability to attack cancer cells.

By Choi He-suk (cheesuk@heraldcorp.com)